Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Design Therapeutics Inc
Healthcare
P/NCAV
0.75x
Ticker
DSGN
Exchange
NASDAQ
Country
United States
Close
3.66 $
Mkt Cap
204.9M $
EV
183.7M $
NCAV Burn Rate
15.1%
Current Ratio
29.58
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
-2.3x
EV/FCF
-3.2x
Dilution
1.0% p.A
Total Net Income
-176.0M $
Cheapness
99.0%
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average